Summary
Gilead Sciences, Inc. (GILD) has filed an 8-K report on October 5, 2006, announcing a significant development: the entry into a definitive Agreement and Plan of Merger with Myogen, Inc. This agreement outlines a two-step acquisition process where Gilead, through its subsidiary Mustang Merger Sub, Inc., will launch a cash tender offer to acquire all outstanding shares of Myogen common stock at $52.50 per share. The acquisition aims to integrate Myogen into Gilead, making it a wholly-owned subsidiary. The offer is contingent upon customary conditions, including the tender of over 50% of Myogen's shares and necessary regulatory approvals. This strategic move signifies Gilead's intent to expand its portfolio through a substantial acquisition, providing an immediate cash payout to Myogen shareholders and potential long-term value creation for Gilead investors if the integration proves successful.
Key Highlights
- 1Gilead Sciences (GILD) to acquire Myogen, Inc. in a two-step merger transaction.
- 2The acquisition will be conducted via a cash tender offer at $52.50 per share of Myogen common stock.
- 3Gilead's subsidiary, Mustang Merger Sub, Inc., will initiate the tender offer.
- 4The transaction is contingent on customary closing conditions, including a majority tender of Myogen shares and regulatory approvals.
- 5Upon successful completion, Myogen will become a wholly-owned subsidiary of Gilead.
- 6Outstanding Myogen stock options will be converted into options to acquire Gilead common stock.